| Zacks Company Profile for Athersys, Inc. (ATHX : NSDQ) |
|
|
| |
| • Company Description |
| Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).
Number of Employees: 104 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.26 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 5,378,866 shares |
| Shares Outstanding: 251.97 (millions) |
| Market Capitalization: $65.66 (millions) |
| Beta: -1.29 |
| 52 Week High: $1.81 |
| 52 Week Low: $0.25 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-52.76% |
-48.28% |
| 12 Week |
-71.99% |
-68.52% |
| Year To Date |
-71.13% |
-64.73% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
3201 CARNEGIE AVENUE
-
CLEVELAND,OH 44115
USA |
ph: 216-431-9900
fax: 216-361-9495 |
ir@athersys.com |
http://www.athersys.com |
|
|
| |
| • General Corporate Information |
Officers
Daniel A. Camardo - Chief Executive Officer and Director
Ismail Kola - Chairman and Director
Ivor Macleod - Chief Financial Officer
John J. Harrington - Executive Vice President; Chief Scientific Officer
Hardy TS Kagimoto - Director
|
|
Peer Information
Athersys, Inc. (CORR.)
Athersys, Inc. (RSPI)
Athersys, Inc. (CGXP)
Athersys, Inc. (BGEN)
Athersys, Inc. (GTBP)
Athersys, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04744L106
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
|
|
Share - Related Items
Shares Outstanding: 251.97
Most Recent Split Date: (:1)
Beta: -1.29
Market Capitalization: $65.66 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.06 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.26 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/08/22 |
|
|
|
| |
